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Abstract
Aim: We previously found that chronic tuberous sclerosis protein 2 (TSC2) deletion induces activation of mammalian target
of rapamycin Complex 1 (mTORC1) and leads to hypertrophy of pancreatic beta cells from pancreatic beta cell-specific TSC2
knockout (bTSC2
2/2) mice. The present study examines the effects of TSC2 ablation on insulin secretion from pancreatic
beta cells.
Methods: Isolated islets from bTSC2
2/2 mice and TSC2 knockdown insulin 1 (INS-1) insulinoma cells treated with small
interfering ribonucleic acid were used to investigate insulin secretion, ATP content and the expression of mitochondrial
genes.
Results: Activation of mTORC1 increased mitochondrial DNA expression, mitochondrial density and ATP production in
pancreatic beta cells of bTSC2
2/2 mice. In TSC2 knockdown INS-1 cells, mitochondrial DNA expression, mitochondrial
density and ATP production were increased compared with those in control INS-1 cells, consistent with the phenotype of
bTSC2
2/2 mice. TSC2 knockdown INS-1 cells also exhibited augmented insulin secretory response to glucose. Rapamycin
inhibited mitochondrial DNA expression and ATP production as well as insulin secretion in response to glucose. Thus,
bTSC2
2/2 mice exhibit hyperinsulinemia due to an increase in the number of mitochondria as well as enlargement of
individual beta cells via activation of mTORC1.
Conclusion: Activation of mTORC1 by TSC2 ablation increases mitochondrial biogenesis and enhances insulin secretion
from pancreatic beta cells.
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Introduction
Type 2 diabetes mellitus is characterised by insulin resistance in
peripheral tissues and pancreatic beta cell failure. Impairment of
insulin secretory capacity has been shown to contribute to the
onset of type 2 diabetes. It remains controversial whether such
impairment of insulin secretory capacity is caused by an
impairment of the functions of pancreatic beta cells alone, whether
it occurs as a result of a decrease in pancreatic beta cell mass alone,
or whether both factors are involved and influence each other
[1–4]. It is therefore important to clarify the mechanism of the
impairment of insulin secretory capacity in order to elucidate the
mechanism of pathogenesis of type 2 diabetes.
Pancreatic beta cells sense ambient glucose concentrations, and
various kinds of metabolites resulting from glucose metabolism in
pancreatic beta cells, such as ATP, are important not only as
energy sources for cells but also as signals for inducing insulin
secretion [5]. Insulin secretion from pancreatic beta cells not only
maintains appropriate blood glucose levels, but also plays an
important role in maintaining the functions of the beta cells
themselves [6,7]. Glucose is metabolised into pyruvic acid via
glycolysis in the pancreatic beta cells, and pyruvic acid enters the
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generation of ATP in mitochondria [8]. It has been reported that
no glucose-responsive insulin secretion is found in MIN6 cells
depleted of mitochondrial DNA [9]. In addition, decreased insulin
secretory capacity, decreased ATP production and abnormalities
in mitochondrial morphology have been found in isolated islets
from mouse models of diabetes and patients with type 2 diabetes
[10,11]. Thus, mitochondria are clearly associated with the
cellular functions of pancreatic beta cells.
We have previously shown that the insulin signalling pathway
is responsible for regulation of both the number and size of
pancreatic beta cells in mice [6,12]. Tuberous sclerosis is an
autosomal dominant disorder characterised by formation of
hamartomas. The genes for tuberous sclerosis complex (TSC) 1
and TSC2 have been identified as causative genes of inherited
TSC [13,14]. Akt-mediated multiple phosphorylation of TSC2
inhibits its ability to act as a GTPase-activating protein toward
Rheb, resulting in activation of mTOR complex 1 (mTORC1)
[15]. Previously, we found that pancreatic beta cell–specific
TSC2 knockout (bTSC2
2/2) mice, in which mTORC1 is
constitutively active, exhibited an increase in the size of individual
beta cells and a decrease in the number of beta cells via a
negative feedback mechanism [12]. Alongside this role in the
regulation of pancreatic beta cell mass, we also found that
ablation of TSC2 in pancreatic beta cells may augment the ability
to secrete insulin [12].
The above results prompted us to consider that mTORC1
might regulate not only pancreatic beta cell mass but also insulin
secretion, and therefore in the present study we analysed the islets
of pancreatic beta cell-specific TSC2 knockout (bTSC2
2/2) mice
and a TSC2 knockdown beta cell line. Here we succeeded in
showing that constitutive activation of mTORC1 enhances insulin
secretion by increasing the number of mitochondria.
Methods
Mice
We generated heterozygous pancreatic beta cell–specific TSC2
knockout (bTSC2
+/2) mice by crossing TSC2
flox/flox mice [12] with
those that express the Cre recombinase gene under the control of
the rat insulin-2 gene [16] as described previously [12]. Animals
were maintained on a 12 h light, 12 h dark cycle and fed normal
chow from the time of weaning (3 weeks old), as described [17,18].
This study was performed in accordance with the guidelines of the
Animal Ethics Committee of Kobe University Graduate School of
Medicine.
Cell culture and transfection of siRNA
At 24 h before transfection, INS-1 cells were re-plated in 12 well
plates (60 mm dishes) and transfected with small interfering RNA
(siRNA) for TSC2 (SMARTpool; Dharmacon, Lafayette, CO,
USA) or scramble controls (Non-Targeting siRNA#2; Dharma-
con) with DharmaFECT2 transfection reagent (Dharmacon). After
a further incubation of 24 h for mRNA or 72 h for protein, the
cells were harvested for evaluation of insulin secretion and mRNA
or protein expression.
Assay of insulin secretion from isolated islets
Islets were isolated from 8-week-old mice as described
previously [18,19]. To assay insulin release, 5 islets were manually
selected, incubated in Krebs-Ringer solution and stimulated at
37uC with various concentrations of either glucose for 1 h or KCl
for 30 min. The islets were then collected by centrifugation, and
the supernatant was assayed for insulin secretion by an ELISA kit
with a mouse insulin standard (Shibayagi Co., Gunma, Japan). For
measurement of islet insulin content, islets were solubilised in acid-
ethanol solution (74% ethanol, 1.4% HCl) overnight at 4uC before
insulin ELISA.
Insulin secretion from INS-1 cells was measured after a 30 min
incubation in Krebs-Ringer-bicarbonate-4-(2-hydroxyethyl)-1-pi-
perazine ethanesulfonic acid (HEPES) buffer (KRBH; 140 mM
NaCl, 3.6 mM KCl, 0.5 mM NaH2PO4, 0.5 mM MgSO4,
1.5 mM CaCl2, 2 mM NaHCO3, 10 mM HEPES, and 0.1%
BSA) containing the indicated stimulators. The insulin content was
determined after extraction with acid ethanol.
ATP content
Isolated islets derived from 8-week-old mice were incubated
with 2.8 mM and 11.2 mM glucose for 1 h after a 30 min
starvation. ATP levels were measured with Cellno ATP Assay Kit
Type N (TOYO BNet Co., Ltd, Tokyo, Japan). Luminescence of
an aliquot of the solution was measured with a luminometer.
INS-1 cells were plated in a 96 well microtest tissue culture plate
(35-3072; BD Falcon, Franklin Lakes, NJ, USA). The next day,
siRNAs for TSC2 and scramble controls were transfected into the
cells. After 48 h, ATP levels were determined using a ‘Cellno’
ATP Assay Kit Type N (TOYO BNet) according to the
manufacturer’s instructions. Briefly, 100 mL of the lysis/assay
solution provided by the manufacturer was added to the cells.
After shaking for 1 min and incubating for 10 min at 23uC,
luminescence of an aliquot of the solution was measured in a
luminometer.
Real-time RT-PCR analysis
Total cellular RNA was extracted from islets isolated from
control and bTSC2
2/2 mice and INS-1 cells with an RNeasy kit
(QIAGEN, Valencia, CA, USA). Real-time RT-PCR analysis of
the total RNA pooled from 6 animals of each genotype was
performed as described previously [20]. For real-time quantitative
reverse transcription and PCR analysis, cDNA synthesized from
total RNA was evaluated in a sequence detector (model 7900;
Applied Biosystems, Foster City, CA, USA) with specific primers
and SYBR Green PCR Master Mix (Applied Biosystems). The
relative abundance of mRNAs was calculated with cyclophilin
mRNA as the invariant control. Details of the primers used for
RT-PCR can be found in Table S1.
MitoTracker Red staining
After washing the cells with phosphate buffered saline, INS-1
cells were stained with 20 nM MitoTracker Red (Invitrogen,
Carlsbad, CA, USA) and subjected to fluorescence-activated cell
sorting (FACS) analysis. A minimum of 10,000 cells were analyzed
on a BD FACSCalibur cell sorter (BD Biosciences, San Jose, CA,
USA) using Cell Quest software (BD Biosciences). The mean
fluorescence intensity was plotted for each treatment.
Electron microscopy
Two TSC2
flox/flox and two bTSC2
2/2 mice were anesthetised
with pentobarbital (25 mg/kg, i.p.) and subjected to cardiac
perfusion with 2% glutaraldehyde and 2% paraformaldehyde
buffered with 0.1 M sodium phosphate buffer (pH 7.2). The
pancreas was excised from each mouse, cut into small pieces and
immersed overnight in the same fixative. The tissue was then
postfixed with 2% osmium tetroxide, block-stained in 1% uranyl
acetate, dehydrated with a graded series of ethanol and embedded
in Epon812 (TAAB). Thin sections were stained with uranyl
acetate and lead citrate before examination under an electron
TSC2 and Insulin Secretion
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1 mm–thick sections were cut and stained with toluidine blue.
Morphometry
Morphometric analysis of the mitochondria in pancreatic beta
cells was performed as described previously [21]. Briefly, electron
micrographs of pancreatic beta cells were taken at a primary
magnification of 65000 (n=23 for control and n=21 for
bTSC2
2/2 mice). After printing at 62.9 the original magnifica-
tion on projection papers, we estimated the mitochondrial density
volume by point counting, using a double-lattice test system with a
1.5 cm spacing. The volume density (Vv) of mitochondria was
expressed as percent volume: Vv=(Pi/Pt)6100 (%), where Pi is
the number of points falling on each mitochondrial structure and
Pt is the number of points falling on the cytoplasm of pancreatic
beta cells.
Immunoblot analysis
We prepared lysates of isolated islets or INS-1 cells as described
[17,18]. The lysates were probed with antibodies to TSC2, Akt,
the phospho-Thr
308 form of Akt, the phospho-Ser
473 form of Akt,
p70 S6 kinase, the phospho-Thr
389 form of p70 S6 kinase, S6, the
phospho-Ser
235 and -Ser
236 forms of S6, voltage-dependent anion-
selective channel (VDAC) protein and cytochrome c oxidase
complex IV (COXIV; all from Cell Signaling, Danvers, MA,
USA). Antibodies to SDH (from Abcam, Cambridge, UK) as well
as that to b-actin (from Sigma-Aldrich, St. Louis, MO, USA) were
also used.
Statistical analysis
Data are presented as means 6 standard errors of the means.
We assessed the significance of differences between independent
means by the Student’s t-test. A P value of ,0.05 was considered
statistically significant.
Results
Insulin secretory response to glucose was enhanced in
islets of bTSC2
2/2 mice
As previously described [12], bTSC2
2/2 mice show hypogly-
cemia and hyperinsulinemia at young ages. The insulin responses
to glucose are also abnormal in bTSC2
2/2 mice, with the plasma
insulin levels after glucose challenge markedly higher than those in
control mice [12]. In the present study, we further examined
glucose-stimulated insulin secretion in isolated islets from control
and bTSC2
2/2 mice at 8 weeks of age. Glucose induced a
concentration-dependent increase in insulin secretion from control
islets in static incubations (Fig. 1A). In contrast, the insulin
response of islets from bTSC2
2/2 mice to glucose was signi-
ficantly greater than that of control islets at both low and high
glucose concentrations, except at 16.8 mM glucose, which showed
no significant difference (Fig. 1A). The islets of bTSC2
2/2 mice
exhibited a normal insulin secretory response to a high
concentration of KCl (Fig. 1B), which elicits insulin release by
inducing membrane depolarisation and calcium influx. Because
bTSC2
2/2 mice have shown an increase in the individual size of
beta cells, the enhanced insulin secretion may be attributable to
increased insulin synthesis. The total insulin content of bTSC2
2/2
mice was significantly higher than that of control mice by ,1.5-
fold (Fig. 1C). We therefore evaluated the insulin response to
glucose normalised to insulin content. After normalisation, the
insulin secretory response to glucose in bTSC2
2/2 mice was still
significantly higher than that in control mice (Fig. 1D), suggesting
that a factor in addition to enhanced insulin synthesis is involved in
the increased insulin response to glucose in islets of bTSC2
2/2
mice.
The insulin secretory response of islets from bTSC2
2/2 mice
was significantly greater than that of control mice at low glucose
concentrations (Fig. 1A and D), suggesting high sensitivity to
glucose in pancreatic beta cells.
Number of mitochondria was increased in islets of
bTSC2
2/2 mice
We next examined whether enhanced activity of mTORC1
resulted in an elevation of the ratio of ATP to ADP, which induced
closure of the ATP-sensitive K-channels, depolarisation of the beta
cell plasma membrane and influx of Ca
2+ via voltage-dependent
Ca-channels, leading to insulin secretion. ATP production was
increased in the islets of bTSC2
2/2 mice at 8 weeks of age under
physiologic condition (11.2 mM glucose) and low glucose
concentration (2.8 mM glucose) (Fig. 2A). We then measured
mRNA expression of all 13 genes encoded in the mitochondria,
comprising 7 subunits of complex I (NADH dehydrogenase; ND1
to ND6), 1 subunit of complex III (cytochrome c oxidoreductase;
cyt b), 3 subunits of complex IV (cytochrome c oxidase; COX1 to
COX3) and 2 subunits of complex V (ATP synthase; atp6 and
atp8). Mitochondrial DNA expression was significantly greater in
islets of bTSC2
2/2 mice than in control mice (Fig. 2B). Electron
microscopy revealed that while the morphology of mitochondria
was not apparently altered in pancreatic b cells of either genotype,
the volume density of mitochondria in pancreatic beta cells of
bTSC2
2/2 mice was significantly increased (about 2.6-fold)
compared with that of control mice at 10 weeks of age (Fig. 2C).
These results suggest that the increased number of mitochondria
resulted in the augmented ATP production in the pancreatic beta
cells of bTSC2
2/2 mice.
TSC2 knockdown INS-1 cells led to enhancement of
insulin secretion
To further confirm the phenotype of bTSC2
2/2 mice described
above, we established TSC2 knockdown INS-1 cells. TSC2 was
knocked down with siRNA. TSC2 protein and Tsc2 mRNA
expression were significantly reduced by approximately 75% at the
protein level and 70% at the mRNA level (Fig. 3A and B).
Reduction in TSC2 expression resulted in an increase in the
phosphorylation of p70 S6 kinase and S6 ribosomal protein,
together with a decrease in the phosphorylation of Akt at Thr
308
and Ser
473 (Fig. 3C). These results indicated that mTORC1 was
activated by depletion of TSC2 and that activated mTORC1
downregulated Akt phosphorylation via a negative feedback
system, which is consistent with the data obtained from analysis
of bTSC2
2/2 mice [12].
We performed a glucose-stimulated insulin release assay with
TSC2 knockdown INS-1 cells. TSC2 knockdown INS-1 cells
exhibited a significant increase in insulin secretion at both low
(2.8 mM) and high (25 mM) glucose concentrations (Fig. 3D). The
insulin secretory response to low glucose concentrations was at a
maximum without further augmentation of insulin secretion at
higher glucose concentrations. These results indicate that
reduction of TSC2 expression induced the activation of
mTORC1, leading to enhancement of insulin secretion in vitro
as well as in vivo as shown above.
TSC2 knockdown augmented mitochondrial number and
function in pancreatic beta cell line cells
We next examined the effect of TSC2 knockdown on the
function of mitochondria from INS-1 cells. Reduction of TSC2
TSC2 and Insulin Secretion
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(Fig. 4A). There was a significant difference in ATP production
between TSC2-knockdown and control INS-1 cells both at 2.8
and 25 mM. High glucose concentrations did not induce further
large increases in glucose-stimulated insulin secretion and ATP
production compared with those at low glucose concentrations,
possibly because they are greatly augmented even at low glucose
concentrations in TSC2-knockdown INS-1 cells. We next
examined the effect of TSC2 knockdown on the expression of
mitochondrial DNA by real-time RT-PCR. Expression of mRNA
by mitochondrial DNA was increased in TSC2 knockdown INS-1
cells, consistent with the results obtained in the islets of bTSC2
2/2
mice (Fig. 4B). We also measured the amount of mitochondria
with MitoTracker Red, which is a fluorescent dye that stains the
mitochondrial membrane. Staining of the mitochondrial mem-
brane in TSC2 knockdown INS-1 cells was about 1.7-fold more
intense than in control INS-1 cells, suggesting an increase in the
number of mitochondria (Fig. 4C). We also examined the
expression of proteins comprising the mitochondrial membrane
by immunoblot analysis. VDAC, COXIV and succinate dehy-
drogenase complex subunit A are mitochondrial membrane
proteins encoded in the nucleus. The expression of these proteins
was increased in TSC2 knockdown INS-1 cells (Fig. 4D). These
results indicate that reduced expression of TSC2 induced an
increase in the number of mitochondria and ATP production in
vitro as well as in vivo.
Rapamycin treatment inhibited enhanced mitochondrial
function in INS-1 cells
To further determine whether enhanced mTORC1 activity is
responsible for the increase in mitochondrial biogenesis, we
treated TSC2 knockdown INS-1 cells with rapamycin, an
mTORC1 inhibitor. Treatment with 20 nM rapamycin reduced
the expression levels of mitochondrial DNA to control levels in
Figure 1. Effect of beta cell–specific ablation of TSC2 on insulin release and insulin content. (A and B) Insulin release in response to the
indicated concentrations of glucose (A) or KCl (B) was measured with islets isolated from control (white bars) or bTSC2
2/2 (black bars) mice at the
age of 8 weeks. Data were obtained from four independent experiments (n=4–6). (C) Insulin content of isolated islets at the age of 8 weeks. (D) The
amount of insulin secreted from the isolated islets normalised to insulin content. Data were obtained from two to three independent experiments
(n=4–6). All data are shown as means6SE of values from 4 animals of each genotype. *P,0.05, **P,0.01 vs the corresponding value for control
mice.
doi:10.1371/journal.pone.0023238.g001
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ATP produced and the insulin secretory response to glucose
were also reduced to the levels in control cells with rapamycin
treatment (Fig. 5B and C). These results suggest that enhanced
mTORC1 activity might induce an increase in mitochondrial
density that increases ATP production and promotes insulin
secretion.
Discussion
Insulin-secreting pancreatic beta cells use their insulin receptors
to transmit insulin signals into the cells. We previously found that
the insulin signalling pathway in pancreatic beta cells is essential
for maintenance of pancreatic beta cell mass [6]. It has been
shown that constitutive activation of mTORC1 by inhibiting the
function of TSC2 is involved in the control of protein synthesis,
cell proliferation, intracellular nourishment and regulation of
transcription factors [15,22–25]. We have recently shown that
pancreatic beta cell–specific TSC2 knockout (bTSC2
2/2) mice
exhibit increased pancreatic beta cell mass due to constitutive
enhancement of mTORC1 activity [12]. In the present study, we
found in pancreatic beta cells that mTORC1 hyperactivity, which
results from inhibition of TSC2 expression, enhanced insulin
secretion by increasing the number of mitochondria.
The 13 types of proteins encoded by mitochondrial DNA are
important subunits of the respiratory chain complexes (I, III, IV
and V), which produce most of the energy required for cellular
activity [26]. Mitochondria are also important to ATP production
in pancreatic beta cells, and the pathogenesis of mitochondrial
diabetes involves pancreatic beta cell failure resulting from
Figure 2. Effect of beta cell–specific ablation of TSC2 on mitochondrial function in pancreatic beta cells. (A) ATP content of isolated
islets of control and bTSC2
2/2 mice at 8 weeks of age. Data are shown as means6SE from 4 mice per each genotype. Data were obtained from three
independent experiments. *P,0.05, **P,0.01 vs the corresponding value for control mice. (B) The abundance of mRNAs for the indicated proteins
was determined by real-time RT-PCR analysis of total RNA isolated from islets of control and bTSC2
2/2 mice. The amounts of the mRNAs in bTSC2
2/2
mice are expressed relative to those in control animals. Data are means6SE of triplicates for pooled total RNA samples from 3 mice of each genotype.
Data were obtained from four independent experiments. *P,0.05, **P,0.01 vs the corresponding value (1.0) for control mice. (C) Upper panel:
Electron micrograph of beta cells of control and bTSC2
2/2 mice at 10 weeks of age. Scale bar: 1 mm. Lower panel: The volume density (%) of
mitochondria in pancreatic beta cells obtained from control and bTSC2
2/2 mice at 10 weeks of age.
doi:10.1371/journal.pone.0023238.g002
TSC2 and Insulin Secretion
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pancreatic islets of bTSC2
2/2 mice exhibited increased mito-
chondrial DNA content and an increased number of mitochon-
dria, as determined by electron microscopy. This increase in the
number of mitochondria is expected to enhance the insulin
secretory capacity by increased ATP production. In fact, we found
that the phenotype of TSC2 knockdown INS-1 cells was restored
by administration of the mTORC1 inhibitor, rapamycin. Thus,
these findings indicate that mTORC1 hyperactivity in pancreatic
beta cells increased the insulin secretory response to glucose via an
increase in the number of mitochondria.
Peroxisome proliferator-activated receptor gamma coactivator
1-alpha (PGC1a) was the first factor discovered in regulation of the
biosynthesis of mitochondria [28,29]. PGC1a is a coactivator of
the transcription factor nuclear respiratory factor 1 (NRF)-1/2,
and NRF-1/2 induces transcription and stabilisation of mitochon-
drial DNA by activating transcription factor A, mitochondrial
(TFAM), which is encoded in the nucleus [28,30–32]. Mice
lacking TFAM specifically in pancreatic beta cells have decreased
insulin secretory capacity associated with a depletion of mito-
chondrial DNA and abnormalities in mitochondrial morphology
[33]. They become diabetic at 5 weeks of age, and their beta cell
Figure 3. Establishment of TSC2 knockdown INS-1 cells. (A, B and C) INS-1 cells treated with scramble siRNA (control) and TSC2 siRNA (DTSC2)
were lysed and subjected to immunoblot analysis with antibodies against TSC2 (A) or the indicated proteins (C), or subjected to real-time PCR
analysis of Tsc2 mRNA (B). Data in B are relative expression values for INS-1 cells treated with scramble siRNA (control) and are means6SE from four
independent experiments. **P,0.01 (D) Insulin secretion in response to the indicated concentrations of glucose for 30 min was assessed in INS-1
cells and expressed per DNA content. Data were obtained from four independent experiments.
doi:10.1371/journal.pone.0023238.g003
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(AMPK) is known to be involved in insulin secretion and cell
survival in pancreatic beta cells [34] and is also another important
factor that regulates the biosynthesis of mitochondria [35,36].
Aminoimidazole carboxamide ribonucleotide, which activates
AMPK, stimulates the biosynthesis of mitochondria through
PGC1a and NRF [37,38].
Previous studies in HEK293 cells have shown that mitochon-
drial functions are enhanced by mTOR, which regulates cell
growth and proliferation according to the nutritional environment
[39]. Recently, it has also been found that rapamycin inhibits the
transcription of mitochondrial genes by dissociating PGC1a from
the complex of TORC1 and the transcription factor YY1 [40].
The facts that PGC1a functions as a coactivator of YY1, that the
YY1-PGC1a complex is necessary for the expression of mito-
chondrial genes and that the binding of the complex is dependent
on TORC1 activity indicate that mitochondrial function is
influenced by the nutritional environment and by growth factors
through mTORC1 activity. This study also showed that
expression levels of mRNA for mitochondrial DNA were
enhanced in INS-1 cells in which TSC2 expression was inhibited
by siRNA and were inhibited by administration of rapamycin,
suggesting that rapamycin inhibited the transcription of mito-
chondrial DNA by dissociating the binding between PGC1a and
YY1.
As mentioned above, the expression of mitochondrial genes is
known to be controlled by PGC1a, but no change in the
expression level of PGC1a was observed in TSC2-knockdown
INS-1 cells (data not shown). Morino et al. reported a decrease in
mitochondrial density and mitochondrial proteins in the skeletal
muscles of patients with type 2 diabetes mellitus, but found no
difference between the expression levels of PGC1a, NRF and
Figure 4. Effect of TSC2 knockdown on the function of mitochondria from INS-1 cells. (A) ATP content of control and TSC2. Cellular ATP
level was measured at 2.8 mM (white bar) and 25 mM (black bar) glucose (n=12). The figure shows data from one representative of four
independent experiments. (B) The level of mRNA expression of mitochondria DNA-encoded genes obtained by real-time PCR. Data are means 6 SE of
triplicate for pooled total RNA samples from three independent experiments. The amounts of the mRNAs in TSC2 INS-1 cells are expressed relative to
those in control cells. (C) Mitochondrial density measured as described in the Material and Methods with MitoTracker Red. Left panel: Mitochondria in
control cells and TSC2 INS-1 cells were stained. Right panel: Relative fluorescence was measured by fluorescence-activated cell sorting analysis after
MitoTracker Red staining. Data were obtained from three independent experiments. (D) Mitochondrial protein expression assessed by western
blotting in INS-1 cells.
doi:10.1371/journal.pone.0023238.g004
TSC2 and Insulin Secretion
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PGC1a requires not only its expression but also modification of
processes such as deacetylation and phosphorylation [42]. After
being deacetylated by Sirt1 or phosphorylated AMPK, PGC1a
functions as a co-activator of transcription factors [43,44]. As
deletion of TSC2 increases AMPK phosphorylation [45,46], we
confirmed that the phosphorylation of AMPK was enhanced in
the pancreatic islets of bTSC2
2/2 mice (data not shown). In the
pancreatic islets of bTSC2
2/2 mice, phosphorylated AMPK
might also increase the number of mitochondria through
activation of PGC1a.
Young bTSC2
2/2 mice have greater pancreatic beta cell mass
and increased secretion of insulin by individual beta cells. We
previously reported that in older bTSC2
2/2 mice, constitutive
hyperactivity of mTORC1 induces a negative feedback mecha-
nism and attenuation of insulin signalling that results in decreased
pancreatic beta cell mass and development of diabetes mellitus
[12]. In addition to attenuation of insulin signalling, we recently
found that excessive insulin secretion induces endoplasmic
reticulum (ER) stress [47]. It is possible, therefore, that
hyperinsulinemia, which is also found in young bTSC2
2/2 mice,
may promote ER stress, leading to apoptosis of pancreatic beta
cells and resulting in reduced pancreatic beta cell mass in older
mice. In addition, it has been reported that constitutively
enhanced mTORC1 activity induces ER stress [48]. That study,
in which mouse embryonic fibroblasts were used, indicated that
the deletion of TSC2 increases the likelihood of ER stress-induced
apoptosis when mTORC1 activity is enhanced. Thus, in
bTSC2
2/2 mice, attenuation of insulin signalling mediated by a
negative feedback mechanism and ER stress due to excessive
insulin secretion are thought to overlap and contribute to a
decrease in pancreatic beta cell mass in older mice.
Figure 5. Effects of rapamycin treatment on mitochondrial function in TSC2 INS-1 cells. (A) Effect of rapamycin treatment on
mitochondrial DNA expression. The ratio of TSC2 INS-1 cells untreated (black bar) and treated (grey bar) with 20 nM rapamycin to control cells. Data
are means 6 SE of triplicate pooled total RNA samples from three independent experiments. #P,0.05; ##P,0.01 TSC2 cells compared with control
(vehicle) cells. *P,0.05; **P,0.01 TSC2 cells treated with rapamycin compared with TSC2 INS-1 cells treated with vehicle. (B) Analysis of rapamycin
effect on ATP production. ATP content of control cells (open bar), TSC2 INS-1 cells treated with (grey bar) and without (lack bar) 20 nM rapamycin
(n=12) Figure shows data from one representative of two independent experiments. (C) Insulin secretion in response to 2.8 mM (open bar) and
25 mM (filled bar) glucose for 30 min was assessed in INS-1 cells and expressed per DNA content. Data are shown with and without 20 nM rapamycin
(n=6). Figure shows data from one representative of three independent experiments.
doi:10.1371/journal.pone.0023238.g005
TSC2 and Insulin Secretion
PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e23238We have shown that constitutive activation of mTORC1
enhances insulin secretion by increasing the number of mitochon-
dria. As seen in the phenotype of bTSC2
2/2 mice, constitutive
hyperactivity of mTORC1 resulted in decreased pancreatic beta
cell mass. Thus, it is suggested that moderate mTORC1 activity is
required to preserve the pancreatic beta cell mass and maintain
the insulin secretory capacity of pancreatic beta cells. As
mentioned above, mTORC1 activity is thought to be involved
in the pathogenesis of type 2 diabetes mellitus through regulation
of the cellular functions of pancreatic beta cells by control of the
number of mitochondria. Further studies of the mechanism of
regulation of mitochondrial functions in pancreatic beta cells are
required for the prevention and treatment of type 2 diabetes
mellitus.
Supporting Information
Table S1 Primers used for real-time RT-PCR analysis.
(DOC)
Acknowledgments
We thank M. Nagano, M. Oya and A. Tanida for technical assistance. This
manuscript was written by Y. Kido.
Author Contributions
Conceived and designed the experiments: M. Koyanagi S-IA T. Matsuda
NH HI TN SS M. Kasuga YK. Performed the experiments: M. Koyanagi
Y. Shigeyama Y. Shibutani AK MF T. Mikami M. Koike. Analyzed the
data: M. Koyanagi S-IA T. Matsuda T. Mikami TH HI MM YU SS M.
Kasuga YK. Contributed reagents/materials/analysis tools: M. Koyanagi
Y. Shibutani YK M. Kasuga. Wrote the paper: M. Koyanagi SS YK.
References
1. Leahy JL (1990) Natural history of beta-cell dysfunction in NIDDM. Diabetes
Care 13: 992–1010.
2. Weyer C, Bogardus C, Mott DM, Pratley RE (1999) The natural history of
insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2
diabetes mellitus. J Clin Invest 104: 787–794.
3. Rhodes CJ (2005) Type 2 diabetes-a matter of beta-cell life and death? Science
307: 380–384.
4. Kasuga M (2006) Insulin resistance and pancreatic beta cell failure. J Clin Invest
116: 1756–1760.
5. Maechler P, Wollheim CB (2001) Mitochondrial function in normal and diabetic
beta-cells. Nature 414: 807–812.
6. Hashimoto N, Kido Y, Uchida T, Asahara S, Shigeyama Y, et al. (2006)
Ablation of PDK1 in pancreatic beta cells induces diabetes as a result of loss of
beta cell mass. Nat Genet 38: 589–593.
7. Ueki K, Okada T, Hu J, Wee Liew C, Assmann A, et al. (2006) Total insulin and
IGF-I resistance in pancreatic beta cells causes overt diabetes. Nat Genet 38:
583–588.
8. Wollheim CB, Maechler P (2002) Beta-cell mitochondria and insulin secretion:
messenger role of nucleotides and metabolites. Diabetes 51 Suppl 1: S37–42.
9. Soejima A, Inoue K, Takai D, Kaneko M, Ishihara H, et al. (1996)
Mitochondrial DNA is required for regulation of glucose-stimulated insulin
secretion in a mouse pancreatic beta cell line, MIN6. J Biol Chem 271:
26194–26199.
10. Anello M, Lupi R, Spampinato D, Piro S, Masini M, et al. (2005) Functional and
morphological alterations of mitochondria in pancreatic beta cells from type 2
diabetic patients. Diabetologia 48: 282–289.
11. Lu H, Koshkin V, Allister EM, Gyulkhandanyan AV, Wheeler MB (2010)
Molecular and metabolic evidence for mitochondrial defects associated with
beta-cell dysfunction in a mouse model of type 2 diabetes. Diabetes 59: 448–459.
12. Shigeyama Y, Kobayashi T, Kido Y, Hashimoto N, Asahara S, et al. (2008)
Biphasic response of pancreatic beta-cell mass to ablation of tuberous sclerosis
complex 2 in mice. Mol Cell Biol 28: 2971–2979.
13. van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, et al. (1997)
Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34.
Science 277: 805–808.
14. The European Chromosome 16 Tuberous Sclerosis Consortium (1993)
Identification and characterization of the tuberous sclerosis gene on chromo-
some 16. Cell 75: 1305–1315.
15. Inoki K, Li Y, Zhu T, Wu J, Guan KL (2002) TSC2 is phosphorylated and
inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4: 648–657.
16. Herrera PL (2000) Adult insulin- and glucagon-producing cells differentiate from
two independent cell lineages. Development 127: 2317–2322.
17. Kido Y, Burks DJ, Withers D, Bruning JC, Kahn CR, et al. (2000) Tissue-
specific insulin resistance in mice with mutations in the insulin receptor, IRS-1,
and IRS-2. J Clin Invest 105: 199–205.
18. Hashimoto N, Kido Y, Uchida T, Matsuda T, Suzuki K, et al. (2005)
PKClambda regulates glucose-induced insulin secretion through modulation of
gene expression in pancreatic beta cells. J Clin Invest 115: 138–145.
19. Kitamura T, Kido Y, Nef S, Merenmies J, Parada LF, et al. (2001) Preserved
pancreatic beta-cell development and function in mice lacking the insulin
receptor-related receptor. Mol Cell Biol 21: 5624–5630.
20. Matsumoto M, Ogawa W, Akimoto K, Inoue H, Miyake K, et al. (2003)
PKClambda in liver mediates insulin-induced SREBP-1c expression and
determines both hepatic lipid content and overall insulin sensitivity. J Clin
Invest 112: 935–944.
21. Koike M, Shibata M, Waguri S, Yoshimura K, Tanida I, et al. (2005)
Participation of autophagy in storage of lysosomes in neurons from mouse
models of neuronal ceroid-lipofuscinoses (Batten disease). Am J Pathol 167:
1713–1728.
22. Kobayashi T, Minowa O, Kuno J, Mitani H, Hino O, et al. (1999) Renal
carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a
germ-line Tsc2 mutation in mice. Cancer Res 59: 1206–1211.
23. Hino O (2003) Hereditary renal carcinogenesis fitting Knudson’s two-hit model:
genotype, environment, and phenotype. Genes Chromosomes Cancer 38:
357–367.
24. Inoki K, Zhu T, Guan KL (2003) TSC2 mediates cellular energy response to
control cell growth and survival. Cell 115: 577–590.
25. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, et al. (2004)
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of
IRS proteins. J Cell Biol 166: 213–223.
26. Wallace DC (1999) Mitochondrial diseases in man and mouse. Science 283:
1482–1488.
27. Velho G, Byrne MM, Clement K, Sturis J, Pueyo ME, et al. (1996) Clinical
phenotypes, insulin secretion, and insulin sensitivity in kindreds with maternally
inherited diabetes and deafness due to mitochondrial tRNALeu(UUR) gene
mutation. Diabetes 45: 478–487.
28. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, et al. (1999)
Mechanisms controlling mitochondrial biogenesis and respiration through the
thermogenic coactivator PGC-1. Cell 98: 115–124.
29. Puigserver P, Wu Z, Park CW, Graves R, Wright M, et al. (1998) A cold-
inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell
92: 829–839.
30. Falkenberg M, Larsson NG, Gustafsson CM (2007) DNA replication and
transcription in mammalian mitochondria. Annu Rev Biochem 76: 679–699.
31. Scarpulla RC (2008) Transcriptional paradigms in mammalian mitochondrial
biogenesis and function. Physiol Rev 88: 611–638.
32. Duncan JG, Fong JL, Medeiros DM, Finck BN, Kelly DP (2007) Insulin-
resistant heart exhibits a mitochondrial biogenic response driven by the
peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory
pathway. Circulation 115: 909–917.
33. Silva JP, Kohler M, Graff C, Oldfors A, Magnuson MA, et al. (2000) Impaired
insulin secretion and beta-cell loss in tissue-specific knockout mice with
mitochondrial diabetes. Nat Genet 26: 336–340.
34. Rutter GA, Leclerc I (2009) The AMP-regulated kinase family: enigmatic targets
for diabetes therapy. Mol Cell Endocrinol 297: 41–49.
35. Reznick RM, Shulman GI (2006) The role of AMP-activated protein kinase in
mitochondrial biogenesis. J Physiol 574: 33–39.
36. Kahn BB, Alquier T, Carling D, Hardie DG (2005) AMP-activated protein
kinase: ancient energy gauge provides clues to modern understanding of
metabolism. Cell Metab 1: 15–25.
37. Bergeron R, Ren JM, Cadman KS, Moore IK, Perret P, et al. (2001) Chronic
activation of AMP kinase results in NRF-1 activation and mitochondrial
biogenesis. Am J Physiol Endocrinol Metab 281: E1340–1346.
38. Winder WW, Holmes BF, Rubink DS, Jensen EB, Chen M, et al. (2000)
Activation of AMP-activated protein kinase increases mitochondrial enzymes in
skeletal muscle. J Appl Physiol 88: 2219–2226.
39. Schieke SM, Finkel T (2006) Mitochondrial signaling, TOR, and life span. Biol
Chem 387: 1357–1361.
40. Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, et al. (2007)
mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha
transcriptional complex. Nature 450: 736–740.
41. Morino K, Petersen KF, Dufour S, Befroy D, Frattini J, et al. (2005) Reduced
mitochondrial density and increased IRS-1 serine phosphorylation in muscle of
insulin-resistant offspring of type 2 diabetic parents. J Clin Invest 115:
3587–3593.
42. Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, et al.
Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+)
and AMPK/SIRT1. Nature 464: 1313–1319.
TSC2 and Insulin Secretion
PLoS ONE | www.plosone.org 9 August 2011 | Volume 6 | Issue 8 | e2323843. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, et al. (2005) Nutrient
control of glucose homeostasis through a complex of PGC-1alpha and SIRT1.
Nature 434: 113–118.
44. Jager S, Handschin C, St-Pierre J, Spiegelman BM (2007) AMP-activated
protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of
PGC-1alpha. Proc Natl Acad Sci U S A 104: 12017–12022.
45. Feng Z, Hu W, de Stanchina E, Teresky AK, Jin S, et al. (2007) The regulation
of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue
specificity, and the role of these gene products in modulating the IGF-1-AKT-
mTOR pathways. Cancer Res 67: 3043–3053.
46. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, et al.
(2005) Akt activates the mammalian target of rapamycin by regulating cellular
ATP level and AMPK activity. J Biol Chem 280: 32081–32089.
47. Asahara S, Matsuda T, Kido Y, Kasuga M (2009) Increased ribosomal
biogenesis induces pancreatic beta cell failure in mice model of type 2 diabetes.
Biochem Biophys Res Commun 381: 367–371.
48. Ozcan U, Ozcan L, Yilmaz E, Du ¨vel K, Sahin M, et al. (2008) Loss of the
tuberous sclerosis complex tumor suppressors triggers the unfolded protein
response to regulate insulin signaling and apoptosis. Mol Cell 29: 541–551.
TSC2 and Insulin Secretion
PLoS ONE | www.plosone.org 10 August 2011 | Volume 6 | Issue 8 | e23238